195533-98-3
基本信息
T 67
T138067 Sodium
T 138067 Sodium
Batabulin sodium
2-Fluoro-1-methoxy-4-((pentafluorophenyl)sulfonamido)benzene sodium salt
2,3,4,5,6-Pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide sodium salt
Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)-, sodium salt
物理化学性质
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO: 125 mg/mL (317.87 mM) |
| 形态 | 结晶固体 |
| 颜色 | Off-white to light yellow |
T67价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-13563A | T67 Batabulin sodium | 195533-98-3 | 5mg | 1500元 |
| 2025/02/08 | HY-13563A | T67 Batabulin sodium | 195533-98-3 | 10mM * 1mLin DMSO | 1650元 |
| 2025/02/08 | HY-13563A | T67 Batabulin sodium | 195533-98-3 | 10mg | 2200元 |
常见问题列表
β-tubulin
Batabulin (T138067; 30-300 nM; 24 hours; MCF7 cells) treatment shows approximately 25-30% tetraploid (4n) DNA content in cells, indicating an arrest at the G2/M cell-cycle boundary.
Batabulin (T138067; 30-300 nM; 24-48 hours; MCF7 cells) treatment shows 25-30% apoptosis. After a 48-hr exposure to 100 nM Batabulin, approximately 50-80% of the cell population is undergoing apoptosis.
Batabulin (T138067) binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Covalent modification occurs at a conserved Cys-239 shared by the β1, β2, and β4 tubulin isotypes. Cells exposed to Batabulin become altered in shape, indicating a collapse of the cytoskeleton, and show an increase in chromosomal ploidy.
Cell Cycle Analysis
| Cell Line: | MCF7 cells |
| Concentration: | 30 nM, 100 nM and 300 nM |
| Incubation Time: | 24 hours |
| Result: | Showed an arrest at the G2/M cell-cycle boundary. |
Apoptosis Analysis
| Cell Line: | MCF7 cells |
| Concentration: | 30 nM, 100 nM and 300 nM |
| Incubation Time: | 24 hours or 48 hours |
| Result: | 25-30% of cells showed the reduced DNA content characteristic of apoptotic cells. |
Batabulin (T138067; 40 mg/kg; intraperitoneal injection; once per week; on days 5, 12, and 19; male athymic nude mice) treatment impairs the growth of the drug-sensitive CCRF-CEM tumors.
| Animal Model: | Male athymic nude mice ( nu/nu ) (6-8 week-old, 20-25 g) injected with CCRF-CEM cells |
| Dosage: | 40 mg/kg |
| Administration: | Intraperitoneal injection; once per week; on days 5, 12, and 19 |
| Result: | Impaired the growth of the drug-sensitive CCRF-CEM tumors. |